Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Civica Rx has struck a deal with the [Blue Cross Blue Shield] Association of US health insurers that will see it gain an investment of $55m to create a new subsidiary that will acquire and develop generic filings for launch in the US from early 2022.
The BCBSA is a federation of 36 separate US health insurance companies that together provide health insurance in the US...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
